Published results from the 96-Week Phase 2b SYMMETRY trial in the New England Journal of Medicine Three presentations at the EASL Congress 2025 highlighted data demonstrating statistically significant ...

On track to initiate FIH study with STRO-004, potential best-in-class Tissue Factor ADC, in the second half of 2025 - - Expanded breadth of preclinical data across pipeline, including STRO-006 and ...